Insiders Updates
Analysts review Nektar Therapeutics’s rating
Nektar Therapeutics’s recently made public that its Chief R&D Officer Zalevsky Jonathan unloaded Company’s shares for reported $19278.0 on Aug
Menu
Nektar Therapeutics’s recently made public that its Chief R&D Officer Zalevsky Jonathan unloaded Company’s shares for reported $19278.0 on Aug
Nektar Therapeutics’s recently made public that its Chief R&D Officer Zalevsky Jonathan unloaded Company’s shares for reported $19278.0 on Aug
Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Nektar Therapeutics
Nektar Therapeutics’s filing revealed that its Chief R&D Officer Zalevsky Jonathan unloaded Company’s shares for reported $7177.0 on May 19
Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its
Nektar Therapeutics’s filing revealed that its Chief R&D Officer Zalevsky Jonathan unloaded Company’s shares for reported $7177.0 on May 19
Nektar Therapeutics’s recent filing unveils that its Chief R&D Officer Zalevsky Jonathan unloaded Company’s shares for reported $7177.0 on May
Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its